AOD-9604 stopped Phase IIb development in 2007 — Metabolic Pharmaceuticals discontinued it after a roughly 2% effect over placebo in obese trial participants. The effect size is the central fact about the compound.
A signal that did not move the obesity endpoint is a different question for someone already lean working on the last 2–3%. The mechanism is narrow: AOD-9604 is the fragment of HGH tied to lipolysis, separated from the growth-promoting region. In the studied profile it acts on beta-3 receptors in fat tissue without elevating IGF-1, shifting glucose, or producing edema. It engages fat metabolism directly rather than through a calorie deficit.
That narrowness is also its ceiling. The compound sits at layer five of a fat-loss stack, behind diet, training, sleep, and a primary compound. The trial readout already mapped what it does and does not do at the population level, and that obesity data anchors how any individual use reads.
| At a Glance | |
|---|---|
| Dosage | Common research-use range 250–500 mcg subcutaneous, daily, anchored near 300 mcg. |
| Protocol | Cycled 12–16 weeks on, 4 weeks off in practitioner write-ups. Morning fasted, 30–60 minutes before activity, on the rationale that mobilized fat needs an oxidative demand. |
| Results timeline | Practitioner convention treats the absence of measurable change by week 4 as the signal the limiting factor sits elsewhere — the studied effect is marginal in already-lean profiles, not a primary fat-loss driver. |
| Side effects | Across six randomized controlled trials the adverse-event rate did not separate from placebo — no IGF-1 elevation, no glucose disruption, no antibody formation reported.² |
| Regulatory status | Phase IIb obesity development discontinued 2007 after a roughly 2% effect over placebo. Not FDA-approved for therapeutic use; holds a 2019 FDA GRAS designation as a food ingredient. WADA prohibited. |
| Best stacked with | Tesamorelin for anabolic support during deficits in stacking write-ups. MOTS-c, L-Carnitine — see Morning Partition Stack below. |
What Is AOD-9604?
AOD-9604 is a synthetic peptide consisting of amino acids 177-191 from the C-terminal region of human growth hormone, with an additional tyrosine residue attached at the N-terminus. The "AOD" stands for "Advanced Obesity Drug," and "9604" was its development code at Metabolic Pharmaceuticals in Australia during the 1990s.
The core concept was elegant: growth hormone has multiple effects—some related to growth and IGF-1 elevation, others related to fat metabolism. Researchers identified a specific fragment (amino acids 177-191) that appeared responsible for GH's lipolytic (fat-releasing) effects. By isolating this fragment, they hoped to create a peptide that burned fat without the diabetogenic effects (glucose elevation, insulin resistance) of full-length growth hormone¹.
The tyrosine modification at position 177 was added to stabilize the molecule and limit residual HGH-like effects on IGF-1 or growth. That mechanistic separation is why the trials did not record the IGF-1 and glucose signals that drive the monitoring protocols around tesamorelin and HGH⁴.
AOD-9604 isolates the fat-mobilization signal from growth hormone without the hormonal complexity — no IGF-1 elevation, no glucose disruption, no growth effects.
How AOD-9604 Works: The Beta-3 Receptor Story
AOD-9604's mechanism centers on beta-3 adrenergic receptors (a type of receptor found primarily on fat cells that triggers fat breakdown when activated).
AOD-9604 binds to fat cells and upregulates (increases the activity of) beta-3 adrenergic receptors. That makes the fat cells more responsive to catecholamines — the body's natural "mobilize fat" signals like epinephrine and norepinephrine.
The downstream effect: increased activity of hormone-sensitive lipase (the enzyme that breaks down stored triglycerides into free fatty acids that can be burned for energy). Fat cells release their contents into the bloodstream.
The Critical Knockout Study
The most compelling mechanistic evidence comes from a 2001 mouse study by Heffernan and colleagues. They tested AOD-9604 in two groups: normal obese mice and beta-3 adrenergic receptor knockout mice (genetically modified to lack these receptors)¹.
The results were clear:
- Normal mice showed significant fat reduction
- Knockout mice showed no response whatsoever
This proved that AOD-9604's fat-loss effects are entirely dependent on beta-3 receptors. No beta-3 receptors, no lipolysis.
Human beta-3 receptor expression varies. Some people carry more active beta-3 signaling than others. That variation is one candidate explanation for the split between users who report a noticeable effect and users who report none — response tracks the receptor profile the compound lands on.
The "Mobilization Without Oxidation" Problem
The mechanism turns on a distinction that is easy to miss: mobilizing fat is not the same as burning fat.
Fatty acids released into the bloodstream still have to be oxidized (burned for energy). Absent activity — absent a metabolic demand for fuel — those fatty acids re-esterify (re-form into triglycerides) and return to fat storage. AOD-9604 opens the door; oxidative demand is what burns what comes out.
That dependency is why the timing convention exists: the mobilization signal pairs with activity that creates oxidative demand, or the released fat re-stores.
The Phase IIb Reality: What the Discontinuation Means
AOD-9604 did not clear Phase IIb for obesity, and development was discontinued. Here is what the readout showed.
The OPTIONS Trial
Metabolic Pharmaceuticals ran the largest study of AOD-9604 in 534 obese adults. After 24 weeks of treatment, the endpoint came in at approximately 2% body weight reduction versus placebo⁶ ⁷.
For context, modern GLP-1 agonists deliver:
- Semaglutide: ~15% weight loss
- Tirzepatide: ~21% weight loss
- Retatrutide: ~24% weight loss (in trials)
A 2% advantage over placebo doesn't meet the FDA's threshold for approving an obesity drug. Development was discontinued in 2007.
Why the Obesity Endpoint Isn't the Only Lens
The distinction that matters: a compound that misses the obesity endpoint is not the same as a compound with no measurable effect.
The OPTIONS trial enrolled obese patients — BMI > 30, often with substantial weight to lose. Against a 50-plus-pound goal, a 2% additional reduction is clinically negligible.
The question for a recomposition context is different: whether a small lipolytic bias registers in an already-lean body pursuing marginal optimization.
At 12% body fat moving toward 10%, the arithmetic shifts. A small fat-mobilization signal, layered onto:
- Optimized training
- Dialed nutrition
- GLP-1 for appetite support
- Tesamorelin for anabolic support
- Activity to oxidize mobilized fat
...is what the final-2-3% rationale rests on. The effect is measurable; it is simply small relative to the obesity threshold.
What the Tolerability Data Recorded
The same trials that showed a small efficacy signal recorded a quiet adverse-event profile. Stier and colleagues ran six randomized, double-blind, placebo-controlled trials measuring AOD-9604's tolerability²:
| Parameter | Trial finding |
|---|---|
| IGF-1 elevation | None detected |
| Glucose metabolism (OGTT) | No effect observed |
| Anti-AOD9604 antibodies | None detected |
| Overall adverse-event rate | Did not separate from placebo |
The pattern across those trials: a small fat-loss signal alongside an adverse-event profile that did not separate from placebo. The trials recorded no IGF-1 elevation, no glucose disruption, and none of the edema or carpal-tunnel signals associated with full-length growth hormone and GHRH analogs.
Where AOD-9604 Fits in a Protocol
AOD-9604 reads as a fine-tuning tool for the final push, not a primary fat-loss driver. The profile segmentation follows from the trial data.
The Profile It Suits
The profile the compound fits, in the recomposition use case:
- Already lean — Sub-15% body fat (men) or sub-22% (women)
- Training consistently — 3-4x per week with structured programming
- Nutrition dialed — Protein adequate, deficit calculated, not guessing
- Higher-leverage tools already in play — GLP-1 agonists, tesamorelin, L-carnitine already used or trialed
- Activity-paired — Morning Zone-2 cardio or fasted training in the routine
- Calibrated expectations — a 2-3% margin, not a dramatic transformation
The Profile It Doesn't
The profiles the trial data argues against:
- Obese or significantly overweight — the obesity endpoint is where GLP-1 agonists carry the effect
- Expecting dramatic results — this is a marginal-effect compound
- Fundamentals not in place — without a dialed diet and training base, the marginal signal has nothing to add to
- No anabolic support layered in — AOD-9604 carries no muscle-protective signal
- Looking for a primary fat-loss tool — this sits at layer five, not layer one
- Subject to drug testing — AOD-9604 is prohibited by WADA⁴
The Hierarchy Framework
Fat loss interventions stack in order of effect size:
| Layer | Intervention | Effect Size |
|---|---|---|
| 1 | Nutrition (deficit) | Massive |
| 2 | Training | Large |
| 3 | GLP-1 agonists | Large |
| 4 | Tesamorelin | Moderate |
| 5 | AOD-9604 | Small |
Layer five only matters when layers one through four are optimized. Adding AOD-9604 while eating at maintenance won't produce visible results — there's no deficit driving oxidation.
| Dosing Protocol | |
|---|---|
| Dose | 300 mcg daily (range: 250-500 mcg) |
| Timing | AM fasted, 30-60 minutes before activity |
| Route | Subcutaneous injection (see injection sites below) |
| Cycle | 12-16 weeks on, 4 weeks off |
| Evaluation | Convention treats no change by week 4 as the signal the limiting factor is elsewhere |
Why Timing Drives the Protocol
The timing convention follows from the mobilization-without-oxidation mechanism above.
The morning-fasted, activity-paired schedule used in practitioner write-ups:
- Fasted state on waking
- The dose goes in (300 mcg subcutaneous)
- A 30-60 minute window for absorption and beta-3 receptor activation
- Zone-2 cardio or training, which creates the oxidative demand
- Mobilized fatty acids meet a fuel demand rather than re-storing
Dosing at night, before sleep, leaves mobilized fatty acids without an oxidative demand to meet, so they re-esterify. The timing exists to line the dose up with that demand.
Reconstitution and Storage
AOD-9604 follows standard peptide protocols:
- Reconstitute with bacteriostatic water
- Store refrigerated (2-8 degrees C) once reconstituted
- Use within 4-6 weeks of reconstitution
- Protect from light and temperature fluctuations
For detailed reconstitution instructions, see the reconstitution guide.
Where to Inject AOD-9604
Subcutaneous injection into abdominal fat is preferred — this area has the highest density of subcutaneous adipose tissue and provides consistent absorption. Rotate between four quadrants around the navel (upper-left, upper-right, lower-left, lower-right), staying at least two inches from the navel itself.
Alternative sites include the outer thigh and back of the upper arm. Avoid areas with scar tissue, bruising, or stretch marks. Use a 29-31 gauge insulin syringe and pinch the skin to ensure subcutaneous (not intramuscular) delivery.
Stacking Protocols
The Morning Partition Stack
This stack targets all three steps of fat utilization: mobilization, transport, and oxidation.
On waking (fasted):
| Compound | Dose | Role |
|---|---|---|
| AOD-9604 | 300 mcg SC | Mobilizes fat from adipocytes (fat cells) |
| L-Carnitine | 500 mg IM | Shuttles fat into mitochondria (the furnace) |
| MOTS-c | 5-10 mg SC | Programs mitochondria to prefer fat as fuel |
Then: 30-60 minutes Zone-2 cardio or training
The logic: AOD opens the door (releases fat). L-carnitine provides the transport. MOTS-c tells the mitochondria to burn what arrives. Activity creates the demand.
Complete Cutting Protocol
For aggressive cuts requiring anabolic protection, AOD-9604 slots into a larger system.
Morning (fasted):
- AOD-9604: 300 mcg SC
- L-Carnitine: 500 mg IM
- Zone-2 cardio: 30-60 minutes
Evening (before bed):
- Tesamorelin: 1-2 mg SC (anabolic protection, visceral fat targeting)
Weekly:
- GLP-1 agonist: Per standard protocol (appetite control, primary fat-loss driver)
Foundation the stack rests on:
- Resistance training: 3-4x per week
- Protein: 1.6-2.2 g/kg body weight
Why the tesamorelin slot carries the stack: AOD-9604 carries no anabolic signal. Under an aggressive deficit, muscle is catabolized alongside fat. Tesamorelin restores pulsatile GH secretion, supporting nitrogen retention and lean-mass preservation. AOD run without that anabolic layer through a hard cut leaves lean mass exposed to disproportionate loss.
AOD-9604 vs Tesamorelin
Both are GH-axis peptides, but they do fundamentally different things. This comparison matters because they're complementary, not interchangeable.
| Property | AOD-9604 | Tesamorelin |
|---|---|---|
| What it is | HGH fragment 177-191 (lipolytic domain only) | Full GHRH(1-44) analog |
| Mechanism | Beta-3 receptor activation on fat cells | Restores pulsatile GH secretion from pituitary |
| IGF-1 effect | None | Elevates (requires monitoring) |
| Muscle protection | None | Yes — nitrogen retention, lean mass preservation |
| Fat targeting | General lipolysis (requires activity to oxidize) | Visceral fat specifically (15-20% VAT reduction) |
| Clinical evidence | Phase IIb failed (~2% vs placebo) | FDA-approved; multiple positive RCTs |
| Monitoring driver | No IGF-1 or glucose signal recorded in trials | IGF-1 and glucose shifts that monitoring tracks |
| Role in a protocol | Optional fine-tuning (layer 5) | Core anabolic protection (layer 4) |
The bottom line: Tesamorelin is the higher-leverage tool with the stronger evidence base. AOD-9604 is the optional add-on for a marginal lipolytic signal. Where only one is in play, tesamorelin carries more. Where both run, the timing convention splits them — tesamorelin at night for GH pulsatility during sleep, AOD in the morning for fasted lipolysis before activity.
AOD-9604 for Men and Women
The Phase I/II safety trials enrolled both men and women, and no significant gender differences emerged in safety or tolerability². Both sexes showed the same pattern: no IGF-1 elevation, no glucose disruption, no antibody formation.
Where gender may matter is in beta-3 receptor expression and fat distribution. Women typically carry more subcutaneous fat (hips, thighs) while men carry more visceral fat (abdomen). Since AOD-9604 works through beta-3 receptors on subcutaneous adipocytes, the response pattern may differ — but clinical trials weren't designed to detect this.
The dosing range does not split by sex: 300 mcg daily (range 250-500 mcg), with body weight the larger variable in dose selection. For a woman on a GLP-1 agonist, AOD as an adjunct sits in the same hierarchy — fundamentals first, GLP-1 for the primary fat-loss effect, tesamorelin for lean-mass support, then AOD as fine-tuning.
Side Effects and Safety
AOD-9604's adverse-event profile is its most-cited feature. The same Phase IIb trials that recorded a small efficacy signal recorded few adverse events².
What's Been Reported
| Effect | Frequency |
|---|---|
| Injection site reactions | Occasional |
| Headache | Occasional |
| Nausea | Rare |
| GI upset | Rare |
What AOD-9604 Does NOT Cause
This list carries more signal than the side-effect table:
- No IGF-1 elevation — unlike HGH or tesamorelin, no growth-factor signal recorded
- No glucose disruption — no OGTT abnormalities detected across the trials
- No edema — no water retention of the kind GHRH analogs produce
- No carpal tunnel — no tingling or numbness reported
- No antibody formation — no immunogenic response detected in the trials
- No pituitary suppression — no effect on the body's own GH production
FDA GRAS Status
In 2019, AOD-9604 received a Generally Recognized As Safe (GRAS) designation from the FDA for use as a food ingredient — an unusual classification for a bioactive peptide. The designation rests on a toxicology-data review at food-ingredient exposure levels. It does not constitute approval for therapeutic use, and the exposure levels it covers are not the doses in the research-use protocols on this page.
WADA Status
AOD-9604 is prohibited by WADA (World Anti-Doping Agency) under category S2: Peptide Hormones, Growth Factors, and Related Substances⁴. Its origin as an HGH fragment places it on the prohibited list even without significant performance enhancement or IGF-1 elevation.
The prohibition is absolute for anyone in a drug-tested pool: AOD-9604 registers as a banned substance regardless of dose or effect.
Frequently Asked Questions
Does AOD-9604 actually work?
Mechanistically, yes — it activates beta-3 adrenergic receptors and stimulates lipolysis. Clinically, the measured effect was modest (~2% over placebo in the obesity trials). The recomposition rationale applies that marginal lipolytic bias to an already-lean body with fundamentals in place, which is a different setting than the obese trial cohort. For obesity-scale fat loss, the GLP-1 agonists carry a much larger measured effect.
What is the recommended AOD-9604 dosage and protocol?
AOD-9604 is dosed at 300 mcg daily by subcutaneous injection in the abdomen, taken in the morning while fasted — 30–60 minutes before activity. Some practitioners use 250–500 mcg depending on body weight, though higher doses haven't shown proportionally better results. Standard cycles are 8 weeks on, 4 weeks off. The key requirement is pairing AOD-9604 with activity — without oxidation demand from Zone-2 cardio or training, mobilized fatty acids simply re-store.
Does AOD-9604 need to be cycled or can I take it continuously?
AOD-9604 is typically cycled in 8-week courses with 4-week breaks, though cycling is less critical than with tesamorelin since AOD-9604 doesn't affect IGF-1 or hormonal axes. The breaks are more about honest assessment — if 8 weeks produced no visible change, continuing isn't productive. Some practitioners run longer courses of 10–12 weeks for people showing slow but steady response.
How long until I see results from AOD-9604?
The studied effect is subtle and develops over 4-8 weeks rather than as a dramatic transformation. In an already-lean profile pairing the dose with consistent morning activity, the reported change is slight and concentrated in stubborn areas. It does not approach the semaglutide-scale magnitude.
What are AOD-9604 side effects?
The reported events were limited — occasional injection-site reactions and headaches, rare nausea. The trials recorded no IGF-1 elevation, no glucose disruption, no edema, and no carpal-tunnel signal. The adverse-event profile across the six trials is among the quietest documented in the peptide literature.
Can I take AOD-9604 with GLP-1 medications?
Yes. AOD-9604 works through beta-3 adrenergic receptors on fat cells; the GLP-1 agonists like tirzepatide and semaglutide work through GIP/GLP-1 receptors in the gut and brain. Different mechanisms, no interaction. The GLP-1 agonist carries the primary effect (appetite suppression, the bulk of the fat loss); AOD adds a marginal lipolytic signal that the recomposition rationale reserves for an already-lean body. The two do not need to be timed relative to each other — GLP-1 weekly, AOD daily AM fasted. The hierarchy runs fundamentals → GLP-1 → tesamorelin → AOD.
How do I store AOD-9604?
Store lyophilized powder refrigerated (2-8 degrees C) or frozen for long-term storage. Once reconstituted with bacteriostatic water, keep refrigerated and use within 4-6 weeks. Protect from light and temperature fluctuations.
Is AOD-9604 the same as HGH fragment?
Yes and no. AOD-9604 is the 177-191 fragment of human growth hormone—specifically the lipolytic portion. However, it's modified (with a tyrosine at position 177) to prevent HGH-like effects on IGF-1 and growth. It's derived from HGH but engineered to isolate only the fat-mobilization signal.
Is AOD-9604 banned in sports?
Yes. WADA prohibits AOD-9604 under peptide hormones and growth factors. Its HGH-fragment origin places it on the prohibited list even without IGF-1 elevation or significant performance enhancement. The ban does not turn on dose or measured effect — the classification alone makes it disqualifying in a tested sport.
Why pair AOD-9604 with tesamorelin?
AOD mobilizes fat but carries no muscle-protective signal. Tesamorelin restores GH pulsatility for anabolic support. AOD run alone during a deficit leaves lean mass exposed to disproportionate loss. The two are complementary in the stacking rationale — tesamorelin as the anabolic anchor through a cut, AOD as the optional lipolytic add-on.
The Bottom Line
AOD-9604 occupies a specific niche: a peptide with a quiet adverse-event profile and a modest measured effect that missed the obesity endpoint and carries a recomposition rationale for already-optimized profiles.
- It acts mechanistically (beta-3 receptor activation, lipolysis stimulation)
- It missed the obesity endpoint (2% effect over placebo)
- Its trials recorded few adverse events (no IGF-1, no glucose disruption, no edema)
- It reads as a fine-tuning tool, not a primary driver
The profile it fits: sub-15% body fat, locked fundamentals, higher-leverage tools (GLP-1, tesamorelin) already in play, and a small additional lipolytic signal sought for stubborn areas.
The profile it doesn't: a need for obesity-scale fat loss, unsettled fundamentals, or an expectation of dramatic results.
AOD-9604 is layer five — it does its work only once layers one through four are built.
Related Topics
- Tesamorelin Guide — GH-axis support with muscle preservation
- Semaglutide Guide — primary fat-loss tool
- Tirzepatide Guide — better body composition data
- MOTS-c Guide — mitochondrial support for the morning stack
- GLP-1 Comparison — compare all GLP-1 options
- Peptide Calculator — peptide preparation
- Retatrutide Guide — Triple-agonist — AOD-9604 used as an adjunct for stubborn areas
References
¹ Beta-3 receptor knockout study — Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 11713213. DOI: 10.1210/endo.142.12.8522
² Safety and tolerability in humans — Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. DOI: 10.4021/jem157w
³ Metabolic effects in obese Zucker rats — Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic effects of AOD9604 on obese Zucker rats. Journal of Molecular Endocrinology. 2000;25(3):287-294. PMID: 11146367. DOI: 10.1159/000053183
⁴ Detection and metabolism (WADA) — Cox HD, Rampton J, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. 2015;7(1):31-38. PMID: 25208511. DOI: 10.1002/dta.1715
⁵ Anti-obesity pharmacotherapy targets — Valentino MA, Lin JE, Snook AE, et al. Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy. Clinical Pharmacology and Therapeutics. 2010;87(6):652-662. PMC: PMC3136748. DOI: 10.1038/clpt.2010.57
⁶ Phase IIb clinical review — Wilding J. AOD-9604 Metabolic. Current Opinion in Investigational Drugs. 2004;5(4):431-437. PMID: 15134286.
⁷ AOD9604 overview — Wikipedia contributors. AOD9604. Wikipedia, The Free Encyclopedia. AOD9604 — Wikipedia
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.